New analogs of vitamin D3

Kidney International, Supplement

Volumn 56, Issue 73, 1999, Pages

  Slatopolsky, Eduardo ^a   Dusso, Adriana ^a   Brown, Alex ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcitriol; Hypercalcimia; Hyperphosphatemia; Parathyroid hormone; Paricalcitol

Indexed keywords

22 OXACALCITRIOL; CALCIPOTRIOL; CALCITRIOL; CALCIUM; COLECALCIFEROL DERIVATIVE; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR; COLECALCIFEROL; DRUG DERIVATIVE;

ARTICLE; BINDING AFFINITY; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; HEMODIALYSIS; HORMONE BLOOD LEVEL; HUMAN; HYPERPHOSPHATEMIA; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PSORIASIS; RECEPTOR DOWN REGULATION; SECONDARY HYPERPARATHYROIDISM; STRUCTURE ACTIVITY RELATION; ANIMAL; REVIEW; SECRETION;

ANIMALS; CALCITRIOL; CHOLECALCIFEROL; HUMANS; HYPERPARATHYROIDISM, SECONDARY; PARATHYROID HORMONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033371962     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.07305.x     Document Type: Article

References (27)

1. SILVER J, RUSSELL J, SHERWOOD LM: Regulation by vitamin D metabolites of messenger RNA for pre-pro-parathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 82:4270-4273, 1985
2. 2D of transcription of the parathyroid hormone gene. Endocrinology 119:2864-2866, 1985
3. 3 suppresses PTH secretion from bovine parathyroid cells in tissue culture. Endocrinology 117:2114-2119, 1985
4. SLATOPOLSKY E, FINCH J, DENDA M, RITTER C, ZHONG M, DUSSO A, MACDONALD PN, BROWN AJ: Phosphorus restriction prevents parathyroid gland growth: High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97:2534-2540, 1996
5. SLATOPOLSKY E, WEERTS C, THIELAND J, HORST R, HARTER H, MARTIN K: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136-2143, 1984
6. DELMEZ JA, TINDIRA C, GROOMS P, DUSSO AS, WINDUS DW, SLATOPOLSKY E: Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest 83:1349-1355, 1989
7. ANDRESS DL, KEITH MD, NORRIS C, COBURN JW, SLATOPOLSKY E, SHERRARD DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274-279, 1989
8. GALLIENI M, BRANCACCIO D, PADOVESE P, ROLLA D, BEDANI P, COLANTONIO G, BRONZIERI C, BAGNI B, TAROLO G: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int 42:1191-1198, 1992
9. DELMEZ JA, SLATOPOLSKY E: Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 19:303-317, 1992
10. QUARLES LD, YOHAY DA, CARROLL BA, SPRITZER CE, MINDA SA, BARTHOLOMAY D, LOBAUGH BA: Prospective trial of pulse oral versus intravenous calcitriol treatment of hypcrparathyroidism in ESRD. Kidney Int 4:1710-1721, 1994
11. MEYRIER A, MARSAC J, RICHET G: The influence of a high calcium carbonate intake on bone disease in patients undergoing hemodialysis. Kidney Int 4:146-153, 1973
12. MORINIERE P, ROUSSEL A, TAHIRI Y, DEFREMONT JF, MAUREL G, JOUDON MC, GUERIS J, FOURNIER A: A substitution of aluminum hydroxide by high doses of calcium carbonate in patients on chronic hemodialysis: Disappearance of hyperaluminaemia and equal control of hyperparathyroidism. Proc Eur Dial Transplant Assoc 19:784-787, 1983
13. SLATOPOLSKY E, WEERTS C, LOPEZ-HILKER S, NORWOOD K, ZINK M, WINDUS D, DELMEZ J: Calcium carbonate as a phosphate hinder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157-161, 1986
14. BROWN AJ, SLATOPOLSKY ES: Mechanisms for the selective actions of vitamin D analogs. In: Vitamin D, edited by FELDMAN D, GLORIEUX F, and PIKE JW, New York, Academic Press, pp 995-1009, 1997
15. 3. J Nutr Sci Vitaminol (Tokyo) 35:529-533, 1989
16. DUSSO A, GUNAWARDHANA S, NEGREA L, FINCH JL, LOPEZ-HILKER S, MORI T, NISHII Y, SLATOPOLSKY E, BROWN AJ: On the mechanisms for the selective action of vitamin D analogs. Endocrinology 128:1687-1692, 1991
17. 3 in rats. J Biochem (Tokyo) 115:373-380, 1994
18. BROWN AJ, FINCH J, GRIEFF M, RITTER C, KUBODERA N, NISHII Y, SLATOPOLSKY E: The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 133:2719-2724, 1993
19. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 30: 105-112, 1997
20. BROWN AJ: Therapeutically active vitamin D analogs. Nephrol Exchange 8:14-19, 1999
21. 3 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 51:317-323, 1997
22. BINDERUP L, BRAMM E: Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 37:889-895, 1988
23. BROWN AJ, RITTER CS, FINCH JL, MORRISSEY J, MARTIN KJ, MURAYAMA E, NISHII Y, SLATOPOLSKY E: The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84:728-732, 1989
24. 3 with an oxygen atom in the side chan. A trial of the development of vitamin D compounds which exhibit potent differentiation-inducing activity without inducing hypercalcemia. FEBS Lett 226: 58-62, 1987
25. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 26:852-860, 1995
26. 2 on calcium and phosphorus resorption in bone. J Am Sct Nephrol 10:980-985, 1999
27. 2 (paricalcitol) safely and effectively reduces the levels of intact PTH in patients on hemodialysis. J Am Soc Nephrol 10:1427-1432, 1998